News
Pfizer Holding To $22B Paxlovid Sales Plan Amid Slow Sales
Pfizer officials stated on an earnings call that while Paxlovid's first-quarter sales may seem to be low, there will be plenty more revenues in the next three months. Paxlovid, Big Pharma's COVID-19 oral antiviral, may soon benefit from agreements in...
News
Teva Settlement Stalls Austedo Generic Rollout Till 2033
Austedo, Teva's tardive dyskinesia (TD) therapy, has great prospects. Now the company only needs to worry about one less generic pharmaceutical presenting a threat to its main growth engine.Teva announced recently that it had reached an agreement with Lupin that...
News
60% Adults And 75% Kids Have COVID-19 Antibodies- CDC Study
According to updated information from the US Centers for Disease Control and Prevention, about 60% of adults plus 75% of children have antibodies suggesting that they've been exposed to COVID-19.
The information comes from a long-term examination of blood...
News
Camzyos, A Likely Blockbuster Heart Drug, Wins FDA Approval
Bristol Myers Squibb has gained approval for one of the year's most anticipated medications, following a brief delay in November. Camzyos, a drug developed by Bristol Myers Squibb, was approved by the FDA to cure symptomatic obstructive hypertrophic cardiomyopathy,...
News
New programme celebrates ChargePoint Technology’s role in COVID-19 vaccine rollout
Specialist Merseyside manufacturing business ChargePoint Technology is set to appear in an ITN production exploring its role in helping to bring the first COVID-19 vaccine to market.
The company will feature in the upcoming programme “How Vaccines Are Changing The...
News
Rinvoq, Blockbuster Drug From Abbvie Gets Fourth FDA Nod
The pharma version of Fast and Furious has a new superhero. How else to characterise AbbVie's Rinvoq's breakthrough effectiveness? The immunology medicine received its fourth FDA approval in five months on April 29th for ankylosing spondylitis. The blessing, however, came...
News
Starting The Journey Dupixent From Sanofi Puts A Good Show
Sanofi's Dupixent is still breaking new ground in inflammatory illnesses five years after receiving FDA approval for the first time in eczema. Bill Sibold, Sanofi's global head of speciality care, believes this since the Regeneron-partnered drug's first-quarter sales increased...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read